US2002019351A1PendingUtilityA1
Treatment of skeletal disorders
Priority: Feb 23, 1998Filed: Sep 27, 2001Published: Feb 14, 2002
Est. expiryFeb 23, 2018(expired)· nominal 20-yr term from priority
A61P 43/00A61P 1/02A61K 38/2264A61P 19/10A61P 19/00A61P 19/08A61P 1/00
39
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates to methods for treating bone loss in a mammal by administering to the mammal a therapeutically effective amount of leptin or a leptin mimetic. This invention also relates to methods for treating bone fracture, enhancing bone healing following facial reconstruction, maxillary reconstruction or madibular reconstruction, enhancing long bone extension, enhancing the healing rate of a bone graft, enhancing prosthetic growth and inducing vertebral synostosis by administering a therapeutically effective amount of leptin or a leptin mimetic. This invention further relates to methods and compositions comprising leptin or a leptin mimetic and estrogen, a selective estrogen receptor modulator or a bisphonate for treating the above-recited diseases and conditions.
Claims
exact text as granted — not AI-modified1 . A method for preventing bone loss or augmenting bone mass in a mammal comprising administering to said mammal a therapeutically effective amount of leptin, a fragment thereof or a leptin mimetic.
2 . A method of claim 1 wherein leptin or a fragment thereof is administered.
3 . A method for treating a mammal having a condition which presents with low bone mass comprising administering to said mammal a therapeutically effective amount of leptin, a fragment thereof or a leptin mimetic.
4 . A method of claim 3 wherein leptin or a fragment thereof is adminstered.
5 . The method of claim 4 wherein osteoporosis, osteotomy, childhood idiopathic bone loss or bone loss associated with periodontitis is treated.
6 . The method of claim 5 wherein osteoporosis is treated.
7 . The method of claim 4 wherein the mammal is a human.
8 . The method of claim 7 wherein the human is a post-menopausal woman or a man over the age of 60.
9 . The method of claim 4 wherein secondary osteoporosis is treated.
10 . The method of claim 9 wherein glucocorticoid-induced osteoporosis, hyperthyroidism-induced osteoporosis, immobilization-induced osteoporosis, heparin-induced osteoporosis or immunosuppressive-induced osteoporosis is treated.
11 . A method for treating a bone fracture in a mammal by administering to said mammal suffering from or susceptible to a bone fracture a therapeutically effective amount of leptin, a fragment thereof or a leptin mimetic.
12 . A method of claim 11 wherein leptin or a fragment thereof is administered.
13 . The method of claim 12 wherein the mammal is a human.
14 . A method for enhancing bone healing following facial reconstruction, maxillary reconstruction or mandibular reconstruction, enhancing long bone extension, enhancing the healing rate of a bone graft, enhancing prosthetic ingrowth, or inducing vertebral synostosis in a mammal by administering to said mammal a therapeutically effective amount of leptin, a fragment thereof or a leptin mimetic.
15 . A method for treating low bone mass or bone fracture in a mammal comprising administering to said mammal a therapeutically effective amount of leptin, a fragment thereof or a leptin mimetic, and estrogen.
16 . A method for treating low bone mass or bone fracture in a mammal comprising administering to said mammal a therapeutically effective amount of leptin, a fragment thereof or a leptin mimetic, and a selective estrogen receptor modulator.
17 . A method of claim 16 wherein leptin or a fragment thereof is adminstered.
18 . A method of claim 17 wherein said selective estrogen receptor modulator is droloxifene.
19 . A method of claim 17 wherein said selective estrogen receptor modulator is raloxifene.
20 . A method of claim 17 wherein said selective estrogen receptor modulator is idoxifene.
21 . A method of claim 17 wherein said selective estrogen receptor modulator is (−)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl)-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalen-2-ol.
22 . A method for treating low bone mass or bone fracture in a mammal comprising administering to said mammal a therapeutically effective amount of leptin, a fragment thereof or a leptin mimetic, and a bisphosphonate.
23 . A method of claim 22 wherein leptin or a fragment thereof is administered.
24 . A method of claim 23 wherein said bisphosphonate is alendronate.
25 . A method of claim 23 wherein said bisphosphonate is risedronate.
26 . A method for enhancing bone healing following facial reconstruction, maxillary reconstruction or mandibular reconstruction, enhancing long bone extension, enhancing the healing rate of a bone graft, enhancing prosthetic ingrowth or inducing vertebral synostosis in a mammal comprising administering to said mammal a therapeutically effective amount of leptin, a fragment thereof or a leptin mimetic, and estrogen.
27 . A method of claim 26 wherein leptin or a fragment thereof is adminstered.
28 . A method for enhancing bone healing following facial reconstruction, maxillary reconstruction or mandibular reconstruction, enhancing long bone extension, enhancing the healing rate of a bone graft, enhancing prosthetic ingrowth or inducing vertebral synostosis in a mammal comprising administering to said mammal a therapeutically effective amount of leptin, a fragment thereof or a leptin mimetic, and a selective estrogen receptor modulator.
29 . A method of claim 28 wherein leptin or a fragment thereof is adminstered.
30 . A method for enhancing bone healing following facial reconstruction, maxillary reconstruction or mandibular reconstruction, enhancing long bone extension, enhancing the healing rate of a bone graft, enhancing prosthetic ingrowth or inducing vertebral synostosis in a mammal comprising administering to said mammal a therapeutically effective amount of leptin, a fragment thereof or a leptin mimetic, and a bisphosphonate.
31 . A method of claim 30 wherein leptin or a fragment thereof is administered.
32 . A pharmaceutical composition comprising a leptin mimetic and a pharmaceutically acceptable carrier or diluent.
33 . A pharmaceutical composition comprising leptin, a fragment thereof or a leptin mimetic, estrogen and a pharmaceutically acceptable carrier or diluent.
34 . A composition of claim 33 comprising leptin or a fragment thereof.
35 . A pharmaceutical composition comprising leptin, a fragment thereof or a leptin mimetic, a selective estrogen receptor modulator and a pharmaceutically acceptable carrier or diluent.
36 . A composition of claim 35 comprising leptin or a fragment thereof.
37 . A pharmaceutical composition comprising leptin, a fragment thereof or a leptin mimetic, a bisphosphonate and a pharmaceutically acceptable carrier or diluent.
38 . A composition of claim 37 comprising leptin or a fragment thereof.
39 . A kit comprising:
a. an amount of leptin, a fragment thereof or a leptin mimetic in a first unit dosage form; b. an amount of estrogen in a second unit dosage form; and c. a container.
40 . A kit of claim 39 comprising leptin or a fragment thereof.
41 . A kit comprising:
a. an amount of leptin, a fragment thereof or a leptin mimetic in a first unit dosage form; b. an amount of a selective estrogen receptor modulator in a second unit dosage form; and c. a container.
42 . A kit of claim 41 comprising leptin or a fragment thereof.
43 . A kit comprising:
a. an amount of leptin, a fragment thereof or a leptin mimetic in a first unit dosage form; b. a bisphonate in a second unit dosage form; and c. a container.
44 . A kit of claim 43 comprising leptin or a fragment thereof.Join the waitlist — get patent alerts
Track US2002019351A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.